U.S., April 4 -- ClinicalTrials.gov registry received information related to the study (NCT07509684) titled 'A Phase Ib/II Study Evaluating Injectable ALK-N001 in Patients With Advanced Solid Tumors' on March 23.
Brief Summary: Primary Objective:
1、 evaluate the preliminary efficacy of ALK-N001 for Injection in patients with advanced solid tumors.
Secondary Objectives:
1. To evaluate the safety of ALK-N001 for Injection in patients with advanced solid tumors.
2. To further evaluate the population pharmacokinetic (PPK) profile of ALK-N001 for Injection in targeted patients with advanced solid tumors.
Exploratory Objectives:
1. To investigate the expression of Legumain in tumor tissues and evaluate the correlation between Leguma...